Browse News
Filter News
Found 630,079 articles
-
After nearly a month in limbo, AstraZeneca will resume Phase III testing of its COVID-19 vaccine candidate in the United States.
-
In the meeting, both the FDA and the U.S. Centers for Disease Control and Prevention presented details about COVID-19 and the requirements for a vaccine.
-
OT-58 is Orphan’s novel investigational enzyme replacement therapy. It is currently in Phase I/II development for classical HCU, a rare metabolic disorder marked by increased levels of plasma homocysteine.
-
Shaun Thaxter, the former chief executive officer of Indivior, was sentenced in federal court Thursday, four months after pleading guilty to one misdemeanor count of sharing false information about the addictive properties of Suboxone Film, an opioid-based product.
-
Foghorn Booms onto Nasdaq with $120M IPO
10/23/2020
Foghorn Therapeutics hits the Nasdaq offering 7.5 million shares at $16 apiece. -
BioSpace Movers & Shakers, Oct. 23
10/23/2020
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
The pharmaceutical supply chain is being pushed to its limit as it prepares to deliver COVID-19 vaccines and therapeutics to the entire world as soon as possible, while continuing to produce and deliver all the usual medications and products.
-
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
-
Bay Area-based insitro snapped up neighboring Haystack Sciences to bolster its machine-learning drug discovery programs with that company’s higher resolution dataset-producing technology.
-
Study Suggests Bayer’s Finerenone Slows CKD Progression in Patients With Kidney Disease and T2D
10/23/2020
The findings from this study were presented at the virtual American Society of Nephrology’s (ASN) Kidney Week 2020 on October 23, and the full study was published in a recent online edition of the New England Journal of Medicine. -
Two Phase III studies showed significant reduction in urinary oxalate excretion in patients of all ages with PH1.
-
Arixa Pharmaceuticals announced on Thursday that Pfizer’s hospital business has agreed to acquire the company. Arixa has been developing oral antibiotics for antibiotic-resistant Gram-negative infections.
-
After discovering promising indicators on the path to the development of Branaplam (LMIO70) for spinal muscular atrophy, Novartis now hopes to repurpose the drug for the treatment of Hungtington’s disease.
-
AMCP Foundation Semiannual Best Poster Competition Virtually Illustrates the Financial Impact of Managed Care Pharmacy Strategies
10/23/2020
AMCP Foundation hosted its most recent Best Poster Competition at AMCP Nexus 2020 Virtual on Wednesday, Oct. 21.
-
Advanced Reimbursement Solutions, LLC., Holds Blue Cross Blue Shield Of Arizona Accountable For Benefits, Advocates For Patient After Insurance Bills Patient $25K
10/23/2020
Advanced Reimbursement Solutions LLC (ARS), a Scottsdale-based medical billing and revenue cycle management enterprise, challenged Blue Cross Blue Shield of Arizona (BCBS of AZ) for its approval and subsequent denial of a double-mastectomy patient.
-
Prime Minister announces funding to advance the development of Canadian COVID-19 vaccine technologies
10/23/2020
As we continue to address the health, social, and economic impacts of COVID-19, the Government of Canada is actively pursuing the purchase and development of vaccines, treatments, and related supplies to protect Canadians from the virus and support our recovery from the pandemic
-
IntelGenx Announces Second Tranche Closing of Private Placement
10/23/2020
IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQB:IGXT) (the “Company” or “IntelGenx”) is pleased to announce that it has closed a private placement (the “Offering”) to certain investors in the United States of U.S.$532,000 principal amount of 8% convertible notes due October 15, 2024 (the “Notes”).
-
ATW Tech provides an update on the private placement and the acquisition of Semeon Analytics Inc.
10/23/2020
ATW Tech Inc. (the "Company" or "ATWTech") (TSX-V: ATW) provides an update on the acquisition of Semeon Analytics Inc. (the "Acquisition") and the private placement (the "Private Placement") that were announced on October 1, 2020. ATW Tech has decided to postpone the estimated closing date of the Acquisition and the Private Placement in order to complete the due diligence of Semeon Analytics Inc.
-
Foghorn Therapeutics Announces Pricing of Initial Public Offering
10/23/2020
Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced the pricing of its initial public offering of 7,500,000 shares of its common stock at a public offering price of $16.00 per share
-
XORTX Reports Annual & Special Meeting Results
10/23/2020
XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX) (OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the results of the Company’s 2020 Annual and Special Meeting of Shareholders held today.